The problem with removing race from colorectal cancer algorithms; Protagonist's drug for rare blood cancer

Removing bias from clinical algorithms isn't as simple as taking race out of the equation, according to new research.

June 16, 2023 Check out STAT+

Sponsored By

Annie Cavanagh/Wellcome Getting rid of bias in clinical calculators isn't as simple as taking race out of the equation A colorectal cancer risk algorithm that included race and ethnicity performed more equally across groups than a model with race redacted.  By Katie Palmer STAT+ | Instead of credible data, PDS Biotech delivers 'results might get better, later' promises The company's drug, called PDS0101, is designed to recruit T cells to attack tumors caused by the human papilloma virus, or HPV. By Adam Feuerstein STAT+ | Moving past regulatory obstacles, Protagonist Therapeutics looks to pivotal trial for its rare blood disorder therapy A rare blood disorder therapy got some primetime attention at the European Hematology Association's annual meeting. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser